Idexx Laboratories (IDXX)

• Market cap: $37.1B
• 1 day: -0.02%
• 5 days: -2.34%
• 1 month: 5.95%
• 3 months: 8.18%
• 6 months: -8.53%
• Year to date: 10.74%
• 1 year: -18.39%
• 5 years: 62.80%
• 10 years: 471.46%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Employees: 11,000

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

7% more first-time investments, than exits

New positions opened: 144 | Existing positions closed: 135

0% more funds holding in top 10

Funds holding in top 10: 12 [Q3] → 12 (+0) [Q4]

1.43% less ownership

Funds ownership: 88.67% [Q3] → 87.24% (-1.43%) [Q4]

3% less funds holding

Funds holding: 1,097 [Q3] → 1,063 (-34) [Q4]

19% less capital invested

Capital invested by funds: $36.5B [Q3] → $29.6B (-$6.97B) [Q4]

25% less repeat investments, than reductions

Existing positions increased: 320 | Existing positions reduced: 426

44% less call options, than puts

Call options by funds: $71.7M | Put options by funds: $128M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $500 10% upside
• Avg. target: $523 16% upside
• High target: $550 21% upside

5 analyst ratings

• positive: 3 60%
• neutral: 2 40%
• negative: 0 0%

Piper Sandler David Westenberg 51% 1-year accuracy 21 / 41 met price target	13% upside $510	Neutral Maintained	10 Feb 2025
Barclays Balaji Prasad 38% 1-year accuracy 16 / 42 met price target	15% upside $520	Overweight Maintained	4 Feb 2025
B of A Securities Michael Ryskin 75% 1-year accuracy 3 / 4 met price target	18% upside $535	Neutral Maintained	4 Feb 2025
Morgan Stanley Erin Wright 50% 1-year accuracy 14 / 28 met price target	21% upside $550	Overweight Maintained	29 Jan 2025
Leerink Partners Daniel Clark 50% 1-year accuracy 1 / 2 met price target	10% upside $500	Outperform Initiated	2 Dec 2024